Magí Farré
Clinical Pharmacologist
Data updated
Research Footprint
Magí Farré appears in 16 tracked papers (2006–2026), most studied alongside MDMA, Ayahuasca and 2C-X, across Healthy Volunteers, Depressive Disorders and Medicinal Chemistry & Drug Development.
Most-cited paper: MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder (203 citations).
Frequent co-authors: Débora González, Marta Torrens and Rafael Torre.
Publication Landscape
How the 16 papers Blossom tracks for Magí Farré line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Magí Farré's publishing grown?
SourcedTracked papers by publication year; 2 earlier papers published before 2012. Click a year for the running total.
Don't read as total output: only the 16 of 16 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Magí Farré publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Magí Farré publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Magí Farré is a clinical pharmacologist based in Spain who specialises in human experimental psychopharmacology and clinical research on classical psychedelics and novel psychoactive substances. His research portfolio spans controlled and observational human pharmacology studies (including work on 2C‑B, mephedrone and MDMA), translational investigations of ayahuasca‑assisted interventions, and genetic moderators of drug response. He works at the interface of pharmacology, psychiatry and addiction medicine and is known for rigorous safety monitoring and careful phenotyping in acute drug challenge studies.
Farré's major contributions include detailed human pharmacology characterisations of 2C‑B and mephedrone, comparative studies situating newer stimulants against MDMA, and clinical investigations exploring psychedelic‑assisted approaches for bereavement and mood disorders. He has also co‑authored systematic reviews and policy‑oriented evidence briefs that contextualise historical and contemporary findings on LSD, ayahuasca and MDMA, and has participated in scholarly debate about risks such as psychedelic‑associated psychosis. Collectively his work has informed safety standards, clinical trial design and translational research agendas in psychedelic medicine.
Key Impact
A prominent European clinical pharmacologist whose human experimental studies and evidence syntheses have substantially advanced understanding of the acute effects, safety profile and therapeutic potential of classical and novel psychedelic compounds.
Collaboration Network
14 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Magí Farré's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Magí Farré is associated with.